HIGHLIGHTS
- who: Blessie Elizabeth Nelson from the Published in partnership with The Hormel Institute, University of Minnesota have published the research: BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study, in the Journal: (JOURNAL)
- what: This trial had statistically significant inferior overall survival with a median OS duration of 6.6 months (P=0.011; HR, 2.4; 95% CI, 1.22-4.7). A variety of treatment regimens were employed in the studies the authors examined; these regimens involved different . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.